Lingkang Pharmaceutical Industry (603669)
Lingkang Pharmaceutical Group Co., Ltd., founded in 2003, is an innovative group enterprise integrating pharmaceutical R & D, production and sales. After ten years of entrepreneurship and development, it has become a high-tech and high-growth group enterprise with strong strength in China's pharmaceutical industry. The company is mainly engaged in the research and development, production and sales of chemical prescription drugs, adheres to the market-oriented product development strategy, and attaches importance to production technology and process innovation. it has a number of varieties with a leading market share in the fields of parenteral nutrition, anti-infection and digestive system, and has a number of reserves and products under research with good market prospects.
The company has outstanding advantages in technology and brand. The group company is highly recognized by the state, province and municipal government. It has won honors such as "National High-tech Enterprise", "China New industrialization contribution Award", "China Patent Excellence Award", "Advanced Unit for implementing famous Brand Strategy", "Hainan Industrial quality and benefit demonstration Enterprise", "Haikou innovative Enterprise" and so on. The company's leading product "alanyl glutamine for injection" won the Ministry of Science and Technology "National key New products" and "injection fructose" won the Ministry of Science and Technology "National Torch Plan Project". A number of pharmaceutical products developed by the company have won the "Science and Technology Progress Award". A number of trademarks such as "Xinkunchang" and "Ruibqi" have been recognized as famous trademarks of Hainan Province by the Hainan provincial government.
The whole factory has passed the GMP certification. The company has small volume injection (including anti-tumor), powder injection (including cephalosporins), freeze-dried powder needles (including cephalosporins, anti-tumor), oral solid preparations and other production lines, the factory has passed GMP certification.
The company has planned and formulated a long-term strategy for drug research and development, has made a number of scientific research achievements and national patents, and has set up five medical research institutes, such as Hainan Haijian Science and Technology Co., Ltd., and has established good cooperative relations with a number of universities and scientific research institutions at home and abroad. At present, the company has a series of products such as antibiotics, nervous system, circulatory system, blood system, digestive system, nutrition and electrolyte supplement.
The company has set up investment promotion offices and regional contact points in various provinces throughout the country, establishing and perfecting a modern marketing management system. In 2008, Zhejiang Ruiji Pharmaceutical Co., Ltd. was established in Hangzhou, Zhejiang Province. The company will further increase the construction of the market network and form a multi-level and multi-channel stable market development system and sales network.
We estimate that the diluted EPS of the company will be 0.80,0.88,1.02 yuan after dilution in 15-17 years. The company has outstanding technical and brand advantages, has a number of varieties with the top market share, and has a number of reserves and products under research with good market prospects. Considering the success rate, stock fundamentals, valuation and the current market sentiment, we give that the first-day pricing range of this IPO is 14.32-16.85 yuan. It is recommended that investors who win the lottery continue to hold
